SE9604795D0 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
SE9604795D0
SE9604795D0 SE9604795A SE9604795A SE9604795D0 SE 9604795 D0 SE9604795 D0 SE 9604795D0 SE 9604795 A SE9604795 A SE 9604795A SE 9604795 A SE9604795 A SE 9604795A SE 9604795 D0 SE9604795 D0 SE 9604795D0
Authority
SE
Sweden
Prior art keywords
pct
pharmaceutical formulation
new pharmaceutical
sec
date
Prior art date
Application number
SE9604795A
Other languages
English (en)
Swedish (sv)
Inventor
Chris Bland
Gerald Steele
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to IDW990482A priority Critical patent/ID21635A/id
Priority to SE9604795A priority patent/SE9604795D0/xx
Publication of SE9604795D0 publication Critical patent/SE9604795D0/xx
Priority to TW086118448A priority patent/TW522015B/zh
Priority to ZA9711055A priority patent/ZA9711055B/xx
Priority to PCT/SE1997/002068 priority patent/WO1998028009A1/en
Priority to EEP199900260A priority patent/EE03857B1/xx
Priority to AT97950542T priority patent/ATE221787T1/de
Priority to UA99074153A priority patent/UA66779C2/uk
Priority to PL97334006A priority patent/PL190493B1/pl
Priority to SK764-99A priority patent/SK283137B6/sk
Priority to JP52867398A priority patent/JP4488538B2/ja
Priority to US09/043,159 priority patent/US6114313A/en
Priority to BRPI9713974-2A priority patent/BR9713974B1/pt
Priority to AU53515/98A priority patent/AU758857B2/en
Priority to RU99115747/14A priority patent/RU2205012C2/ru
Priority to CN97180744A priority patent/CN1121875C/zh
Priority to DE69714616T priority patent/DE69714616T2/de
Priority to ES97950542T priority patent/ES2182133T3/es
Priority to PT97950542T priority patent/PT1007094E/pt
Priority to CA002275153A priority patent/CA2275153C/en
Priority to CZ0220199A priority patent/CZ300635B6/cs
Priority to DK97950542T priority patent/DK1007094T3/da
Priority to HU0000572A priority patent/HU226616B1/hu
Priority to EP97950542A priority patent/EP1007094B1/de
Priority to NZ336027A priority patent/NZ336027A/en
Priority to SI9730403T priority patent/SI1007094T1/xx
Priority to IL13044997A priority patent/IL130449A0/xx
Priority to KR1019997005584A priority patent/KR100552880B1/ko
Priority to TR1999/01412T priority patent/TR199901412T2/xx
Priority to SA97180719A priority patent/SA97180719B1/ar
Priority to ARP970106075A priority patent/AR010377A1/es
Priority to MYPI97006175A priority patent/MY121982A/en
Priority to IS5064A priority patent/IS1897B/is
Priority to NO19993067A priority patent/NO327142B1/no
Priority to HK00105598A priority patent/HK1026366A1/xx
Priority to FR15C0060C priority patent/FR15C0060I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9604795A 1996-12-20 1996-12-20 New pharmaceutical formulation SE9604795D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
IDW990482A ID21635A (id) 1996-12-20 1996-12-20 Komposisi farmasi untuk pengeringan beku
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation
TW086118448A TW522015B (en) 1996-12-20 1997-12-08 Pharmaceutical compositions for freeze drying
ZA9711055A ZA9711055B (en) 1996-12-20 1997-12-09 Pharmaceutical compositions for freeze drying
TR1999/01412T TR199901412T2 (xx) 1996-12-20 1997-12-11 Dondurarak kurutma i�lemi i�in farmakolojik terkipler.
DE69714616T DE69714616T2 (de) 1996-12-20 1997-12-11 Pharmazeutische Zusammensetzungen enthaltend ein Nucleotid Analog, geeignet für Gefriertrocknung
CA002275153A CA2275153C (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying
AT97950542T ATE221787T1 (de) 1996-12-20 1997-12-11 Pharmazeutische zusammensetzungen enthaltend ein nucleotid analog, geeignet für gefriertrocknung
UA99074153A UA66779C2 (uk) 1996-12-20 1997-12-11 Фармацевтична композиція для лікування порушення агрегації тромбоцитів та спосіб її одержання (варіанти)
PL97334006A PL190493B1 (pl) 1996-12-20 1997-12-11 Kompozycja farmaceutyczna do liofilizacji i jej zastosowanie oraz sposób jej wytwarzania
SK764-99A SK283137B6 (sk) 1996-12-20 1997-12-11 Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy
JP52867398A JP4488538B2 (ja) 1996-12-20 1997-12-11 凍結乾燥のための医薬組成物
US09/043,159 US6114313A (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying
BRPI9713974-2A BR9713974B1 (pt) 1996-12-20 1997-12-11 composiÇço farmacÊutica, processo para preparaÇço e uso da mesma.
AU53515/98A AU758857B2 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying
RU99115747/14A RU2205012C2 (ru) 1996-12-20 1997-12-11 Фармацевтические композиции для сушки вымораживанием
CN97180744A CN1121875C (zh) 1996-12-20 1997-12-11 适于冷冻干燥的药物组合物
PCT/SE1997/002068 WO1998028009A1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying
ES97950542T ES2182133T3 (es) 1996-12-20 1997-12-11 Composiciones farmaceuticas para liofilizar.
PT97950542T PT1007094E (pt) 1996-12-20 1997-12-11 Composicoes farmaceuticas compreendendo um analogo de nucleotido adequadas para liofilizacao
EEP199900260A EE03857B1 (et) 1996-12-20 1997-12-11 Ravimkoostised külmkuivatamiseks
CZ0220199A CZ300635B6 (cs) 1996-12-20 1997-12-11 Farmaceutický prostredek, zpusob jeho výroby a použití
DK97950542T DK1007094T3 (da) 1996-12-20 1997-12-11 Farmaceutiske sammensætninger, der omfatter en nucleotidanalog til frysetørring
HU0000572A HU226616B1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions suitable fer freeze drying comprising nucleotide analogs and process for preparing them
EP97950542A EP1007094B1 (de) 1996-12-20 1997-12-11 Pharmazeutische Zusammensetzungen enthaltend ein Nucleotid Analog, geeignet für Gefriertrocknung
NZ336027A NZ336027A (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying comprising a nucleotide analogue, mannitol and a modifying additive which is sodium chloride or a polyol
SI9730403T SI1007094T1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying
IL13044997A IL130449A0 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying
KR1019997005584A KR100552880B1 (ko) 1996-12-20 1997-12-11 동결 건조용 제약 조성물
SA97180719A SA97180719B1 (ar) 1996-12-20 1997-12-17 تركيبات صيدلية للتجفيف بالتجميد
ARP970106075A AR010377A1 (es) 1996-12-20 1997-12-19 Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos.
MYPI97006175A MY121982A (en) 1996-12-20 1997-12-19 Pharmaceutical compositions for freeze drying
IS5064A IS1897B (is) 1996-12-20 1999-06-03 Lyfjablöndur sem fela í sér kirnishliðstæður sem eru hentugar til frostþurrkunar
NO19993067A NO327142B1 (no) 1996-12-20 1999-06-21 Farmasoytisk preparat som omfatter en nukleotidanalog, mannitol og et modifiserende additiv, anvendelse av nevnte preparat samt fremgangsmate for dets fremstilling
HK00105598A HK1026366A1 (en) 1996-12-20 2000-09-05 Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying
FR15C0060C FR15C0060I2 (fr) 1996-12-20 2015-09-07 Compositions pharmaceutiques comprenant un analogue d'un nucleotide destinees a la lyophilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE9604795D0 true SE9604795D0 (sv) 1996-12-20

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation

Country Status (36)

Country Link
US (1) US6114313A (de)
EP (1) EP1007094B1 (de)
JP (1) JP4488538B2 (de)
KR (1) KR100552880B1 (de)
CN (1) CN1121875C (de)
AR (1) AR010377A1 (de)
AT (1) ATE221787T1 (de)
AU (1) AU758857B2 (de)
BR (1) BR9713974B1 (de)
CA (1) CA2275153C (de)
CZ (1) CZ300635B6 (de)
DE (1) DE69714616T2 (de)
DK (1) DK1007094T3 (de)
EE (1) EE03857B1 (de)
ES (1) ES2182133T3 (de)
FR (1) FR15C0060I2 (de)
HK (1) HK1026366A1 (de)
HU (1) HU226616B1 (de)
ID (1) ID21635A (de)
IL (1) IL130449A0 (de)
IS (1) IS1897B (de)
MY (1) MY121982A (de)
NO (1) NO327142B1 (de)
NZ (1) NZ336027A (de)
PL (1) PL190493B1 (de)
PT (1) PT1007094E (de)
RU (1) RU2205012C2 (de)
SA (1) SA97180719B1 (de)
SE (1) SE9604795D0 (de)
SI (1) SI1007094T1 (de)
SK (1) SK283137B6 (de)
TR (1) TR199901412T2 (de)
TW (1) TW522015B (de)
UA (1) UA66779C2 (de)
WO (1) WO1998028009A1 (de)
ZA (1) ZA9711055B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
AU2010319612B2 (en) 2009-11-11 2016-01-14 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
EP2964233B1 (de) 2013-03-09 2021-12-15 Chiesi Farmaceutici S.p.A. Verfahren zur behandlung, verringerung der inzidenz und/oder prävention von ischämischen ereignissen
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
WO2016114818A1 (en) * 2015-01-14 2016-07-21 The Medicines Company Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
EP3641784A1 (de) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Verfahren zur prävention von thrombosen bei systemischen-zu-lungenarterienfisteln

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (de) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Ａｔｐ凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.

Also Published As

Publication number Publication date
FR15C0060I2 (fr) 2016-04-22
WO1998028009A1 (en) 1998-07-02
ZA9711055B (en) 1998-07-08
MY121982A (en) 2006-03-31
CN1240362A (zh) 2000-01-05
HK1026366A1 (en) 2000-12-15
JP4488538B2 (ja) 2010-06-23
FR15C0060I1 (de) 2015-10-23
IS5064A (is) 1999-06-03
RU2205012C2 (ru) 2003-05-27
HUP0000572A3 (en) 2002-10-28
TR199901412T2 (xx) 1999-08-23
AU758857B2 (en) 2003-04-03
PL190493B1 (pl) 2005-12-30
BR9713974A (pt) 2000-04-11
IL130449A0 (en) 2000-06-01
ATE221787T1 (de) 2002-08-15
CN1121875C (zh) 2003-09-24
EE03857B1 (et) 2002-10-15
HU226616B1 (en) 2009-04-28
NZ336027A (en) 2001-03-30
ID21635A (id) 1999-07-08
DE69714616D1 (de) 2002-09-12
UA66779C2 (uk) 2004-06-15
EP1007094A1 (de) 2000-06-14
ES2182133T3 (es) 2003-03-01
DE69714616T2 (de) 2003-04-03
AR010377A1 (es) 2000-06-07
DK1007094T3 (da) 2002-10-28
HUP0000572A2 (hu) 2001-05-28
AU5351598A (en) 1998-07-17
BR9713974B1 (pt) 2010-02-23
SK283137B6 (sk) 2003-03-04
KR20000069598A (ko) 2000-11-25
CZ300635B6 (cs) 2009-07-08
CA2275153C (en) 2008-03-25
NO327142B1 (no) 2009-05-04
JP2001507022A (ja) 2001-05-29
PL334006A1 (en) 2000-01-31
SA97180719B1 (ar) 2006-05-13
EE9900260A (et) 2000-02-15
NO993067D0 (no) 1999-06-21
NO993067L (no) 1999-08-09
CA2275153A1 (en) 1998-07-02
TW522015B (en) 2003-03-01
SI1007094T1 (en) 2003-02-28
EP1007094B1 (de) 2002-08-07
IS1897B (is) 2003-10-20
CZ220199A3 (cs) 1999-11-17
US6114313A (en) 2000-09-05
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
PT1007094E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
SE9604795D0 (sv) New pharmaceutical formulation
SE9601421D0 (sv) New composition
KR930700492A (ko) 혈당 저하제로서의 3-아릴-2-하이드록시프로피온산 유도체 및 그의 유사체
NZ290420A (en) Phenyl or pyridyl-amide substituted dihydro benzofurans; medicaments
BR0012908A (pt) Método para preparar uma composição oral estável antibacteriana contendo uma lupulona hidrogenada, e, composição oral estável antibacteriana
EP0931788A3 (de) Metalloproteinase-Inhibitoren
DK0751789T3 (da) Gel til behandling af hudsygdomme og til desinfektion af huden
BR9910863A (pt) Formulações farmacêuticas para igf/ igfbp
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
DK0937074T3 (da) Benzonaphthyridiner som bronkiale terapeutiske midler
SE9702680D0 (sv) New formulation
CY1108110T1 (el) Παραγοντες και μεθοδοι για προστασια, θεραπεια και επιδιορθωση συνδετικου ιστου
ES2168336T3 (es) Composiciones farmaceuticas que contienen bifosfonato y un agente contra la resorcion para inhibir la perdida osea.
NO985981D0 (no) Insulinpreparater som inneholder NaCl
HU9603200D0 (en) Use of gel formulations as dressing agents
EA200200396A1 (ru) Фармацевтические композиции фибринолитического агента
SE9803760D0 (sv) Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
DE69311541D1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
DK0917460T3 (da) Cyclosporin-formulering
GB2324091A (en) Metalloproteinase inhibitors
SE9604752D0 (sv) Formulation and use
ES2091039T3 (es) Nuevos bis-fenil-hexenos.
FI964448A (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
PT925781E (pt) Composicao para despigmentacao